Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody

Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates

Published:2023-07-07 Issue:7 Volume:27 Page:1258-1268
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Fernandez-Cerezo Lara¹^ORCID,Holstein Melissa²,Thirumalairajan Srinath³,Romanini Dante⁴,Kos Pavlo⁵,Raglione Thomas⁶,Bulger Paul G.⁷^ORCID

Affiliation:

1. Department of Process Research & Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

2. Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, Massachusetts 01434, United States

3. Chemical Process and Analytical Development, Seagen Inc., 22515 29th Drive SE, Bothell, Washington 98021, United States

4. Commercial Biologics Technical Operations, Gilead Sciences, 300 The American Road, Morris Plains, New Jersey 07950, United States

5. Drug Substance Development, Merck Healthcare KGaA, Franfurter Str. 250, 64293 Darmstadt, Germany

6. Chemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States

7. Department of Analytical Research & Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00137

Reference50 articles.

1. Please visit www.iqconsortium.org for more information.

2. Key metrics to expanding the pipeline of successful antibody–drug conjugates

3. The oncology market for antibody–drug conjugates

4. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products (accessed Jan 03, 2023).

5. Antibody–Drug Conjugates—A Tutorial Review

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices;Organic Process Research & Development;2024-07-30

2. Risk Evaluation of N-Nitrosamines in Drug-Linker Intermediates Used To Generate Antibody–Drug Conjugates;Organic Process Research & Development;2024-07-25

3. Kinetic models towards an enhanced understanding of diverse ADC conjugation reactions;Frontiers in Bioengineering and Biotechnology;2024-07-11

4. Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates;Organic Process Research & Development;2023-06-28